



PTO/SB/08e/s (08-03)
Approved for use through 07/31/2003. OMB 0351-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1448A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/791,148	
			Filing Date	March 1, 2004	
			First Named Inventor	Amedeo Leonardi	
			Art Unit	1614	
			Examiner Name	TBA	
Sheet	1	of	3	Attorney Doctel Number	04266/100M619-US3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SUS	A	6,517,871	02/11/2003	Venkatesh et al.	
	B	6,395,728	05/28/2002	Webb et al.	
	C	6,204,281	03/20/2001	Webb et al.	
	D	6,071,939	08/08/2000	Gaviraghi et al.	
	E	2004/0254178	12/18/2004	Grigorieff et al.	
	F	2004/0002529	01/01/2004	Sada et al.	
	G	2003/0181500	09/25/2003	Lee et al.	
	H	2003/0175344	09/18/2003	Wald et al.	
	I	2003/0008904	01/09/2003	Buch, Jan	
	J	2002/0098241	07/25/2002	Venkatesh, Gopadi M.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
SUS	1	WO 03/097045		11/27/2003	Novartis Pharma GMBH		
	2	WO 03/014084		02/20/2003	Recordati Ireland Limited		
	3	WO 02/43807		08/06/2002	Novartis AG		
	4	WO 02/35046		05/02/2002	EGHOLM, et al.		
	5	WO 02/06253		01/24/2002	Norvartis-Erfindungen Verwaltungsgesellschaft MBH		
	6	WO 01/13800		03/01/2001	Medicure Inc.		
	7	WO 00/27397		05/18/2000	Glaxo Group Limited, et al.		
	8	WO 00/27396		05/18/2000	Glaxo Group Limited, et al.		
	9	WO 00/02543		01/20/2000	Norvartis-Erfindungen Verwaltungsgesellschaft MBH		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
SUS	10	Aranda, F.J. et al. (2000) "Therapeutic Efficacy and Tolerability of Lercanidipine versus Candesartan, Alone or in Combination, in Mild-Moderate Essential Hypertensives," <i>Journal of Hypertension</i> 18(2): S152 (abstract)		
	11	Epstein, MD, Murray (2001) "Lercanidipine - A Novel Dihydropyridine Calcium-Channel Blocker," <i>Heart Disease</i> 3: 398-407		
Examiner Signature				Date Considered 2/18/05

Substitute for form 1448A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/791,148	
			Filing Date	March 1, 2004	
			First Named Inventor	Amedeo Leonardi	
			Art Unit	1614	
			Examiner Name	TBA	
Sheet	2	of	3	Attorney Docket Number	04266/100M619-US3

55	12	Gasser et al. (1999) "Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension", <i>J Clin Basic Cardiol</i> , 2:169-174
	13	Grandi et al. (2002) "Aldosterone Antagonist Improves Diastolic Function in Essential Hypertension", <i>Hypertension</i> , 40:847-852
	14	Kurashivili, Ramaz B. et al. "24-Hour Monitoring in Hypertensive Patients with Type II Diabetes Mellitus: Combination Therapy with Lacidipine and Irbesartan (undated abstract)
	15	Mancia et al. (1998) "Clinical Advantages of Lipophilic Dihydropyridines", <i>Blood Pressure</i> , 7(suppl 2):23-26
	16	Mancia and Grassi (1994) "Combination treatment of hypertension", <i>High Blood Pressure</i> , 3 (suppl to No. 4): 5-7
	17	Martell et al. (2003) "Association of Lercanidipine Plus Enalapril to Control Blood Pressure," presented at the American Society of Hypertension, May 14-17, 2003, New York, NY (abstract)
	18	Martell et al. (2002) "Asociaciones Terapéuticas en El Control de la Presión Arterial," Poster and Abstract presented at the 7 th Reunión Nacional Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión Arterial, <i>Hipertensión</i> 19(2), Abstract 61T
	19	Martell et al. (2002) "Asociaciones Farmacológicas en Hipertensos con Factores de Riesgo Cardiovascular," Poster and Abstract presented at the 7 th Reunión Nacional Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión Arterial, <i>Hipertensión</i> 19(2), Abstract 69T
	20	McClellan and Jarvis (2000) "Lercanidipine: A Review of its Use in Hypertension", <i>Drugs</i> , 60:1123-1140
	21	Messerli, MD, Franz (2002) "Vasodilatory Edema: A Common Side Effect of Antihypertensive Therapy," <i>Current Cardiology Reports</i> 4: 479-482
	22	Morgan, Trevor et al. (2002) "A Comparison of Candesartan, Felodipine, and Their Combination in the Treatment of Elderly Patients with Systolic Hypertension," <i>American Journal of Hypertension</i> 15(6): 544-549
	23	Omboni and Zanchetti (1998) "Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements", <i>J Hypertens</i> , 16:1831-1838
	24	Ramsay et al. (1999) "Guidelines for management of hypertension: report of the third working party of the British Hypertension Society", <i>J of Human Hypertension</i> , 13:589-592
	25	Recordati et al. (2000) "Effects of a reversible 'nephrectomy' on renal sympathetic activity and blood pressure in the rat: evidence for an acute angiotensin-mediated hypertension", <i>Journal of Hypertension</i> , 18:1277-1287
	26	Rengo and Romis (1997) "Activity of Lercanidipine in Double-Blind Comparison with Nitrendipine in Combination Treatment of Patients with Resistant Essential Hypertension", <i>J of Cardiovascular Pharmacology</i> , 29(suppl 2):S54-S58
	27	Ruzicka, MD, Marcel et al. (2002) "Combination therapy as first-line treatment of arterial hypertension," <i>Can. J. Cardiol.</i> 18(12): 1317-1327
	28	Sarafidis et al. (2004) "The Effect of Telmisartan and Lercanidipine on Blood Pressure and Insulin Resistance in Hypertensive Patients," <i>Review of Clinical Pharmacology and Pharmacokinetics, International Edition</i> 18:60-66

Examiner Signature		Date Considered	7/16/05
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/791,148		
		Filing Date	March 1, 2004		
		First Named Inventor	Amedeo Leonardi		
		Art Unit	1614		
		Examiner Name	TBA		
Sheet	3	of	3	Attorney Docket Number	04266/100M619-US3

29	van Zwieten (2000) "The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy", <i>Cardiovascular Research</i> , 45:82-91	
30	Weir AJH (1998) "The Rationale for Combination Versus Single-Entity Therapy in Hypertension", <i>American Journal of Hypertension</i> , 11:183S-169S	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	7/18/05
-----------------------	---	--------------------	---------